Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).
Keywords: Compassionate use; Coronavirus disease 2019; Remdesivir; Severe acute respiratory syndrome coronavirus 2.
【저자키워드】 severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019, Remdesivir, compassionate use, 【초록키워드】 COVID-19, Treatment, coronavirus disease, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Coronavirus disease 2019, Efficacy, coronavirus, clinical trial, pandemic, Respiratory failure, Pneumonia, severe respiratory failure, drugs, Remdesivir, severe acute respiratory syndrome Coronavirus, China, Viral pneumonia, Viral, mechanisms, respiratory, disease, compassionate use, Evidence, clinical presentation, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, viral pathogen, pharmacological, reported, appear, therapeutic drug, 【제목키워드】 Coronavirus disease 2019, Remdesivir,